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Aim of database: The aim of the Danish Heart Failure Registry (DHFR) is to monitor and 
improve the care of patients with incident heart failure (HF) in Denmark.
Study population: The DHFR includes inpatients and outpatients ($18 years) with incident 
HF. Reporting to the DHFR is mandatory for the Danish hospital departments treating patients 
with incident HF. Final decision to register a patient in the DHFR is made by a cardiologist 
to ensure the validity of the diagnosis. Approximately 42,400 patients with incident HF were 
registered in the DHFR in July 2015.
Main variables and descriptive data: The main variables recorded in the DHFR are related to 
the indicators for quality of care in patients with incident HF: performance of echocardiography, 
functional capacity (New York Heart Association functional classification), pharmacological therapy 
(angiotensin converting enzyme/angiotensin II antagonist inhibitors, beta-blockers, and mineralo-
corticoid receptor antagonist), nonpharmacological therapy (physical training, patient education), 
4-week readmission rate, and 1-year mortality. Furthermore, basic patient characteristics and prog-
nostic factors (eg, smoking and alcohol) are recorded. At the annual national audit in the DHFR, 
the indicators and standards for good clinical quality of care for patients with HF are discussed, 
and recommendations are reported back to clinicians to promote quality improvement initiatives. 
Furthermore, results and recommendations are communicated to the public in an annual report. 
All standards for the quality indicators have been met at a national level since 2014. Indicators for 
treatment status 1 year after diagnosis are under consideration (now prevalent HF).
Conclusion: The DHFR is a valuable tool for continuous improvement of quality of care in 
patients with incident HF in Denmark. Furthermore, it is an important resource for the Danish 
registry-based HF research.
Keywords: heart failure, registry, quality, indicators, processes of care, variables, quality 
improvement
Introduction
The Danish Heart Failure Registry (DHFR) is a nationwide registry established in 2003 
as a part of a large nationwide quality improvement initiative aimed at monitoring and 
improving the quality of care for patients with specific severe diseases, including heart 
failure (HF).1 Reporting to the DHFR is mandatory for all hospital departments treating 
patients with incident HF. The DHFR achieved complete nationwide coverage in 2005.
Aim of database
The aim of the DHFR is to monitor and support implementation of evidence-based 
treatment and care of patients with incident HF, and it is anticipated that it will improve 
the overall performance in patients with HF.
Clinical Epidemiology
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Study population
The DHFR includes data on inpatients and outpatients with 
incident HF. The HF diagnosis is made by a cardiologist 
using the criteria of the European Society of Cardiology.2 At 
discharge or at the first outpatient contact, patients with one 
of the following diagnoses (primary diagnosis) are screened 
for inclusion in the DHFR: I11.0, I13.0, I13.2, I42.0, I42.6, 
I42.7, I42.9, I50.0, I50.1, and I50.9. All diagnoses are made 
in accordance with the International Classification of Dis-
eases 10th edition, which has been used for all admissions 
and outpatient contacts in Denmark since 1995.
Patients enrolled in the DHFR have to meet the following 
inclusion criteria: age 18 years or older, a first time hospital 
contact with HF as the primary diagnosis, and
•	 symptoms of HF, usually dyspnea, increased fatigue, fluid 
retention, and
•	 objective signs of HF at rest, for example, reduced sys-
tolic function and/or diastolic dysfunction/elevated filling 
pressure and/or
•	 clinical response to specific HF treatment.
Thus, enrollment in the registry requires both manifesta-
tion of symptoms and objective signs of HF at rest and/or 
response to treatment of HF.
Exclusion criteria are previously verified diagnosis and treat-
ment of HF, isolated right-sided HF, and HF secondary to val-
vular heart diseases, noncorrectable structural heart diseases, or 
tachycardia-induced HF (often atrial fibrillation). Furthermore, 
patients discharged with a diagnosis of acute myocardial infarc-
tion and concomitant HF are not included. These patients will be 
included if they are later hospitalized with HF or are referred to 
an outpatient cardiology clinic for treatment of HF.
Only patients with a Danish unique personal identification 
number (CPR number) are enrolled in the database, allowing 
accurate linkage between the DHFR and other nationwide admin-
istrative registries at the individual level. The decision to register 
a patient in the DHFR is made by a cardiologist to ensure the 
validity of the incident HF diagnosis according to the inclusion 
and exclusion criteria. By July 2015, the DHFR contained data 
on ∼42,400 patients with incident HF. Each year, 3,700–3,900 
patients with incident HF are registered in the DHFR.
Patients in the DHFR are selected in accordance with 
the exclusion criteria to establish a homogeneous population 
with HF. Thus, the DHFR will not reflect the total incidence 
of HF in the general Danish population due to inclusion and 
exclusion criteria. Moreover, less-severe cases of HF may be 
treated in the primary health care sector (general practice) 
and these cases are not recorded in the DHFR.
Main variables
The variables recorded in the DHFR are related to basic 
characteristics, prognostic factors, diagnostic tests, func-
tional capacity (symptom severity), pharmacological 
therapy, nonpharmacological therapy, readmission, and 
mortality (Table 1). The quality indicators consist of five 
processes and two outcome indicators3 defined by the DHFR 
multi disciplinary board to monitor good clinical quality of 
treatment and care for patients with incident HF. The indi-
cators are echocardiography, New York Heart  Association 
functional classification, medications,  physical training, 
patient education, rate of readmission, and mortality 
(Table 2). Both the prognostic factors and the evidence-
based quality indicators are based on national4 and inter-
national guidelines.2,5
The use of echocardiography and New York Heart Asso-
ciation functional classification, 4-week readmission rate, 
and 1-year mortality are reported for all patients, whereas 
the use of angiotensin converting enzyme/angiotensin II 
antagonist inhibitors and beta-blockers, physical training, 
and patient education are evaluated in patients with systolic 
HF and left ventricular ejection fraction #40%. The use of 
mineralocorticoid receptor antagonist is evaluated in patients 
with left ventricular ejection fraction #35%.
Until now, the DHFR only contains information about 
patients with incident HF. At the audit conducted in 2015, the 
multidisciplinary board decided to supplement the registry 
with qualitative indicators for treatment status of the patients’ 
treatment 1 year after diagnosis.
Data are registered for patients with HF admitted to 
hospital or at first outpatient visit by a cardiologist and the 
nursing staff. The process for registration of data has been 
developed to ensure data accuracy and for standardizing 
procedures for all clinicians.6
The DHFR board is obliged to ensure that the indicators 
reflect the quality of HF treatment and that the collection 
of data is simple and feasible in routine clinical settings. 
Systematic literature reviews are performed regularly, and 
the latest review was conducted in 2015.7
Local, regional, and national audits are conducted yearly. 
Performance data, completeness of registered patients, 
and variables are reported for each hospital department, 
region, and at a national level, making comparison of data 
possible.
At the annual national audit in the DHFR, the indicators 
and standards for good clinical quality in treatment and care 
for patients with HF are discussed and recommendations are 
Clinical Epidemiology 2016:8submit your manuscript | www.dovepress.com
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Table 1 Main variables in the Danish Heart Failure Registry
Main group Variable Description/comments
Basic characteristics Civil registration number Unique personal identification number including date of birth 
and sex
Age
Sex
Status of hospital contact Inpatient or outpatient
Date of admission/outpatient contact
Date of discharge Only hospitalized patients
Status at discharge Alive or dead
Discharge diagnosis I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.9, I50.0, I50.1, and 
I50.9 (ICD-10)
Prognostic factors Acute myocardial infarction Yes or no
Stroke Yes or no
Diabetes Yes or no
COPD Yes or no
Hypertension Yes or no
Serum creatinine $150 μmol/L Yes or no
Electrocardiogram Yes or no
Heart rhythm SR, AF/AFL, or other
Alcohol intake #14/21 units per week, .14/21 units per week or na
Smoking Smoker, previous smoker, never smoker, or na
Diagnostic test Echocardiography Yes, date for echocardiography or no. If yes, the exact value 
for LvEF or LvEF ,25%, 25% # LvEF # 35%, 35% , LvEF 
# 40%, 40% , LvEF , 50%, LvEF $50%
Functional capacity NYHA functional classification NYHA functional classification I, II, III, IV, or na
Pharmacological  
therapy
Status of ACE/ATII inhibitor treatment at first  
contact
Yes or no
Initiation of ACE/ATII inhibitor treatment Yes and starting date or no
Status of beta-blocker treatment at first contact Yes or no
Initiation of beta-blocker treatment Yes and starting date or no
Status of MRA at first contact Yes or no
Initiation of MRA treatment Yes and starting date or no
Nonpharmacological  
therapy
Physical training Yes and starting date of training in hospital or date for 
referral to training in municipality or no
Patient education Yes and starting date or no
Readmission 4-week rate of acute readmission Yes and date for readmission or no
Mortality 1-year mortality Alive or dead according to the Danish Civil Registration 
System
Abbreviations: ACE/ATII, angiotensin converting enzyme/angiotensin II antagonist; AF/AFL, atrial fibrillation/atrial flutter; COPD, chronic obstructive pulmonary disease; 
ICD-10, International Classification of Diseases 10th edition; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; na, not available; NYHA 
functional classification, New York Heart Association functional classification; SR, sinus rhythm.
reported back to clinicians and communicated to the public 
in the final annual report. Furthermore, the board decides 
whether any changes to the quality measures are warranted, 
and discusses potential new indicators.
In 2014 and 2015, all indicators were met at a national 
level.8 The coverage and completeness of indicator variables 
and prognostic factors from 2004 to 2015 are shown in 
Table 3. The completeness of the reported variables for each 
indicator was between 91% and 100% in 2015.8
Only patients with a first time primary diagnosis of HF are 
included in the registry. We assume that careful screening of 
the patients by a cardiologist means that virtually all patients 
included in the database have HF. But a precise validation of 
the accuracy has not been performed.
The coverage of the DHFR is routinely evaluated by 
matching data with the administrative data in the Danish 
National Patient Register,9 which includes data on all hospital 
contacts in Denmark since 1977. A total of 82% of incident 
HF cases had been recorded in the DHFR in 2015.8 This 
relatively low coverage may partly be explained by patients 
being treated for HF in the hospital and, thus, registered 
accordingly in the Danish National Patient Register, but not 
meeting the inclusion/exclusion criteria for entry into the 
DHFR. To obtain high coverage of the registry, a continuous 
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Table 2 Process and outcome indicators in the Danish Heart Failure Registry
Indicator area Indicator Time frame Type Standard 
(%)
Echocardiography Proportion of patients who undergo 
echocardiography
#6 months before or #7 weekdays after 
admission or first outpatient contact
Process $90
NYHA functional 
classification
Proportion of patients who undergo NYHA 
functional classification
#12 weeks after admission or first 
outpatient contact
Process $90
Medication Proportion of patients with reduced systolic function 
(LvEF #40%) treated with ACE/ATII inhibitors
#8 weeks after admission or first 
outpatient contact
Process $90
Proportion of patients with reduced systolic function 
(LvEF #40%) treated with beta-blockers
#12 after admission or first outpatient 
contact
Process $80
Proportion of patients with reduced systolic function 
(LvEF #35%) treated with MRA
#12 weeks after admission or first 
outpatient contact
Process $35
Physical training Proportion of patients with reduced systolic function 
(LvEF #40%) referred to individual physical training
#12 weeks after admission or first 
outpatient contact
Process $30
Patient education Proportion of patients with reduced systolic function 
(LvEF #40%) who were started on a structured 
patient education
#12 weeks after admission or first 
outpatient contact
Process $80
Readmission Proportion of patients hospitalized acutely within 
4 weeks after discharge or first outpatient contact
#4 weeks after discharge from the 
hospital or first outpatient contact
Outcome #10
Mortality Proportion of patients who die 1 year after 
admission to hospital or first outpatient contact
#1 year after admission or first 
outpatient contact
Outcome #20
Abbreviations: ACE/ATII, angiotensin converting enzyme/angiotensin II antagonist; LvEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; 
NYHA functional classification, New York Heart Association functional classification.
Table 3 Coverage and completeness of indicator variables and prognostic factors 2004 to 2015
Annual report, year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Number of patients 2,598 2,452 2,429 2,731 2,996 3,229 3,447 3,876 3,909 3,957 3,631 3,735
Coverage, national level (%) na 76* 69* 73* 72** 79 84 82 83 84 81 82
Completeness of indicator variables*** (%)
 Echocardiography 94 100 100 100 100 99 100 99 100 100 100 100
 NYHA functional classification 94 100 100 100 99 100 100 100 100 100 100 100
 ACE/ATII inhibitors na 67 81 85 85 87 86 89 92 93 93 94
 Beta-blockers na 36 52 60 87 90 87 89 92 93 93 94
 MRA na 6 17 24 85 89 86 87 90 90 91 92
 Physical training 51 68 83 83 86 87 84 87 89 89 88 91
 Patient education 63 78 89 88 87 88 85 88 91 91 92 93
 Readmission na 100 100 100 99 100 100 99 99 100 100 100
 Mortality na 100 100 100 100 100 100 100 100 100 100 100
Completeness of prognostic factors (%)
 Smoking na na 79 82 85 84 86 88 89 92 93 92
 Alcohol na na 71 75 78 80 82 83 85 89 88 89
 LvEF 72 73 81 86 90 92 93 97 98 99 99 99
 Creatinine na na na na na na 100 100 100 100 100 98
 AMI 80 81 89 92 98 98 98 99 98 99 99 99
 Stroke 72 72 85 88 98 98 98 99 98 98 98 98
 Hypertension 76 77 87 91 99 99 99 99 99 99 99 99
 COPD 71 72 85 88 98 98 98 99 98 99 99 98
 Diabetes 76 77 89 93 99 99 99 99 99 99 99 99
Notes: *Self-reported coverage. From 2009, coverage is estimated from the registration of patients in the Danish National Patient Register. **Self-reported coverage. 
In 2008, coverage was also estimated from the Danish National Patient Register, reaching only 43%. ***Data completeness refers to whether or not all the information 
necessary to estimate the indicator was available in the data resource.
Abbreviations: ACE/ATII, angiotensin converting enzyme/angiotensin II antagonist; AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; LvEF, 
left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; na, not available; NYHA functional classification, New York Heart Association functional 
classification.
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effort by the departments is performed to review the lists of 
inpatients and outpatients with the primary diagnosis of HF 
and to assess whether the inclusion and exclusion criteria in 
the DHFR are fulfilled.
Follow-up
Six of the seven indicators selected in the DHFR are related 
to care processes and outcome within a period of 12 weeks 
from the date for first contact to either hospital or outpatient 
clinic. Information on the seventh indicator on 1-year mortal-
ity is obtained from the Danish Civil Registration System,10 
where vital status is updated continuously.
The participating departments receive regular feed-
back on their performance regarding the process indi-
cators to ensure data validation and to support quality 
improvement.
Examples of research
The population-based data and a high number of patients 
with incident systolic and nonsystolic HF makes the DHFR 
data suitable for clinical epidemiology research. A study 
has shown a substantial improvement in the DHFR process 
indicators from 2003 to 2010 among patients diagnosed 
with incident HF. In the same period, the 1-year mortality 
decreased from 20.5% to 12.8%.11
An analysis based on the DHFR and demographic data 
indicates that HF is not diagnosed and treated adequately in 
people above 75 years.12 Studies on patients with systolic 
HF in the DHFR indicate equal effect of different types of 
angiotensin converting enzyme inhibitors and beta-blockers 
on mortality in patients with HF.13,14
Administrative issues and funding
The DHFR is funded and operated by the Danish Clinical 
Registries,15 which are financed and owned by the five Danish 
regions. A clinical epidemiologist and a quality consultant 
from the Danish Clinical Registries are affiliated to the 
DHFR. The epidemiologist has the responsibility for the 
analytical methods, analysis of data, and interpretation of 
results in the DHFR. The quality consultant is responsible 
for communication and support to the DHFR as well as com-
munication with the participating hospitals.
Conclusion
The DHFR is a valuable tool for improving the quality 
of care for patients with HF and a valuable source for 
research. Since the establishment in 2003, the care of 
patients with incident HF admitted to the Danish hospitals 
and registered in the DHFR has improved with a higher 
level of achievement of quality indicators and declining 
1-year mortality.
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